Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director | May 29, 2025 | June 02, 2025 |
| Aceragen, Inc.IDRA · Entity 110652 | CHIEF OPERATING OFFICER | July 06, 2022 | July 07, 2022 |
| DBV Technologies S.A.DBVT · Entity 5096 | Director | August 01, 2023 | August 03, 2023 |
| KalVista Pharmaceuticals, Inc.KALV · Entity 39180 | Director | September 30, 2021 | October 01, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date May 29, 2025 · Filed June 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,041 |
Reported balance
After 2025-05-29 transaction · row 1
1 source rowRow 1 · 2025-05-29 · Exercise / conversion · Acquired 9,387 · Balance 44,041 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-29 · Exercise / conversion · Disposed 9,387 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,107 |
Reported balance
After 2025-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-29 · Grant · Acquired 8,107 · Balance 8,107 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.29 · Expires 2035-05-28 | Direct | 13,793 |
Reported balance
After 2025-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-29 · Grant · Acquired 13,793 · Balance 13,793 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held.
F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.
Aceragen, Inc.
Report date July 06, 2022 · Filed July 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2032-07-06 | Direct | 66,500 |
Reported balance
After 2022-07-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-06 · Grant · Acquired 66,500 · Balance 66,500 F1: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on July 6, 2026, with 25% vesting on July 6, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on July 6, 2026, with 25% vesting on July 6, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer.
DBV Technologies S.A.
Report date August 01, 2023 · Filed August 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2023-08-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-08-01 · Purchase · Acquired 15,000 · Balance 20,000 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"), each of which currently represents one-half of one Ordinary Share. F2: Represent the ADS price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"), each of which currently represents one-half of one Ordinary Share.
F2: Represent the ADS price.
KalVista Pharmaceuticals, Inc.
Report date September 30, 2021 · Filed October 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.45 · Expires 2031-09-29 | Direct | 10,000 |
Reported balance
After 2021-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-30 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests over a 12 month period: 1/12th on October 30, 2021, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a 12 month period: 1/12th on October 30, 2021, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015275 · form4-06022025_060611.xml · derivative · entry 4 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,107 Underlying: Common Stock · 8,107 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 13,793 | $0.00 Strike: $22.29 | $0.00 |
DisclosureSEC source: 0001415889-25-015275 · form4-06022025_060611.xml · derivative · entry 3 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,793 Underlying: Common Stock · 13,793 shares Expires 2035-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015275 · form4-06022025_060611.xml · derivative · entry 2 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015275 · form4-06022025_060611.xml · nonDerivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 9,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015085 · form4-05312024_060506.xml · derivative · entry 4 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,387 Underlying: Common Stock · 9,387 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 15,959 | $0.00 Strike: $14.62 | $0.00 |
DisclosureSEC source: 0001415889-24-015085 · form4-05312024_060506.xml · derivative · entry 3 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,959 Underlying: Common Stock · 15,959 shares Expires 2034-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015085 · form4-05312024_060506.xml · derivative · entry 2 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-015085 · form4-05312024_060506.xml · nonDerivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:40 UTC | DBV Technologies S.A. DBVT · Entity 5096 | PurchaseOrdinary Shares | 15,000 | $1.62 | $24,300.00 |
DisclosureSEC source: 0001209191-23-044458 · doc4.xml · nonDerivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"), each of which currently represents one-half of one Ordinary Share. F2 · price: Represent the ADS price. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 6,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034699 · doc4.xml · derivative · entry 8 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,652 Underlying: Common Stock · 6,652 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 11,045 | $0.00 Strike: $23.90 | $0.00 |
DisclosureSEC source: 0001209191-23-034699 · doc4.xml · derivative · entry 7 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,045 Underlying: Common Stock · 11,045 shares Expires 2033-05-31 F3 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 8,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034699 · doc4.xml · derivative · entry 6 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,552 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034699 · doc4.xml · nonDerivative · entry 3 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 17:30 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 66,500 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001415889-22-007543 · form4-07072022_020737.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires 2032-07-06 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on July 6, 2026, with 25% vesting on July 6, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 00:21 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035663 · doc4.xml · derivative · entry 2 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,552 Underlying: Common Stock · 8,552 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 00:21 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 14,368 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001209191-22-035663 · doc4.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,368 Underlying: Common Stock · 14,368 shares Expires 2032-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 07, 2022 Filed Jun 6, 2023 01:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034699 · doc4.xml · derivative · entry 5 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 07, 2022 Filed Jun 6, 2023 01:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,391 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034699 · doc4.xml · nonDerivative · entry 2 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 17:43 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 41,500 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001415889-22-003751 · form4-04042022_020426.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires 2032-04-01 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on January 24, 2026, with 25% vesting on January 24, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 20:42 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001415889-22-000792 · form4-01262022_050117.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-24 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 24, 2022. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 24, 2023 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 16:56 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.45 | $0.00 |
DisclosureSEC source: 0001209191-21-058487 · doc4.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-09-29 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on October 30, 2021, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 16:05 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 66,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001415889-21-003586 · form4-07122021_040712.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires 2031-07-08 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:42 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 6,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043043 · doc4.xml · derivative · entry 2 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,391 Underlying: Common Stock · 6,391 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:42 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 11,637 | $0.00 Strike: $24.88 | $0.00 |
DisclosureSEC source: 0001209191-21-043043 · doc4.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,637 Underlying: Common Stock · 11,637 shares Expires 2031-06-21 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 22, 2021 Filed Jun 6, 2023 01:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 3,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034699 · doc4.xml · derivative · entry 4 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,059 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 22, 2021 Filed Jun 6, 2023 01:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 3,059 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034699 · doc4.xml · nonDerivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 16:10 UTC | Aceragen, Inc. IDRA · Entity 110652 | PurchaseCommon Stock | 50,000 | $1.19 | $59,500.00 |
DisclosureSEC source: 0001415889-21-003112 · form4-06212021_040601.xml · nonDerivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,843 Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 16:58 UTC | DBV Technologies S.A. DBVT · Entity 5096 | PurchaseWarrant (right to buy) · Derivative | 6,837 | $7.12 Strike: $13.09 | $48,679.44 |
DisclosureSEC source: 0001209191-21-039890 · doc4.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,837 Underlying: Ordinary Shares · 6,837 shares Expires 2025-06-10 F1 · derivative.exercise_price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021. F1 · price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021. Read SEC document |
| March 05, 2021 Filed Mar 5, 2021 17:55 UTC | Aceragen, Inc. IDRA · Entity 110652 | PurchaseCommon Stock | 10,000 | $3.90 | $38,950.00 |
DisclosureSEC source: 0001415889-21-001353 · form4-03052021_020310.xml · nonDerivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,843 Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 16:43 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001179110-21-000155 · edgar.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 4, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 4, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:38 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantDirector Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001209191-20-053397 · doc4.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 1, 2020, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:37 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantDirector Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001209191-20-053396 · doc4.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 1, 2020, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 3,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-038979 · doc4.xml · derivative · entry 2 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,059 Underlying: Common Stock · 3,059 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 5,579 | $0.00 Strike: $52.73 | $0.00 |
DisclosureSEC source: 0001209191-20-038979 · doc4.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,579 Underlying: Common Stock · 5,579 shares Expires 2030-06-22 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| September 27, 2019 Filed Sep 30, 2019 17:23 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | PurchaseCommon Stock | 7,962 | $11.87 | $94,497.79 |
DisclosureSEC source: 0001567619-19-018888 · doc1.xml · nonDerivative · entry 2 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.85 to $11.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:23 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | PurchaseCommon Stock | 2,038 | $11.90 | $24,252.20 |
DisclosureSEC source: 0001567619-19-018888 · doc1.xml · nonDerivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,038 Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 21:14 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $25.24 | $0.00 |
DisclosureSEC source: 0001209191-19-039525 · doc4.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-06-26 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| April 22, 2019 Filed Apr 23, 2019 17:29 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantDirector Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $26.40 | $0.00 |
DisclosureSEC source: 0001567619-19-009059 · doc1.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-04-21 F1 · derivative.exercise_date: The option vests over a 3 year period: 1/36th vests on May 22, 2019, after which 1/36th of the total shares vest monthly, subject to reporting person's continued service through each vesting date. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:07 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001415889-18-000913 · form4-06082018_020624.xml · derivative · entry 2 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-05 F2 · security: Annual committee grant. F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:07 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001415889-18-000913 · form4-06082018_020624.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| March 02, 2018 Filed Mar 2, 2018 23:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | PurchaseCommon Stock | 3,000 | $22.52 | $67,560.00 |
DisclosureSEC source: 0001415889-18-000338 · form4-03022018_030351.xml · nonDerivative · entry 4 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 23:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | PurchaseCommon Stock | 2,000 | $24.52 | $49,040.00 |
DisclosureSEC source: 0001415889-18-000338 · form4-03022018_030351.xml · nonDerivative · entry 3 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 23:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | PurchaseCommon Stock | 3,000 | $24.09 | $72,270.00 |
DisclosureSEC source: 0001415889-18-000338 · form4-03022018_030351.xml · nonDerivative · entry 2 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 23:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | PurchaseCommon Stock | 2,000 | $23.02 | $46,040.00 |
DisclosureSEC source: 0001415889-18-000338 · form4-03022018_030351.xml · nonDerivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 21:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.85 | $0.00 |
DisclosureSEC source: 0001415889-17-001230 · form4-07192017_020738.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-07-16 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable at the end of each 3-month period following the date of ACADIA's 2017 Annual Meeting of Stockholders, or June 13, 2017. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 22:16 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.25 | $0.00 |
DisclosureSEC source: 0001415889-17-000993 · form4-06142017_030610.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.